Last reviewed · How we verify
Repeated rocuronium dose
Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction.
Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively inhibits the nicotinic acetylcholine receptor at the neuromuscular junction. Used for Skeletal muscle relaxation during surgery.
At a glance
| Generic name | Repeated rocuronium dose |
|---|---|
| Sponsor | University Hospital, Antwerp |
| Drug class | Non-depolarizing neuromuscular blocking agent |
| Target | Nicotinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
This inhibition prevents acetylcholine from binding to the receptor, leading to muscle paralysis. The effect is reversible with anticholinesterases or by allowing time for spontaneous recovery.
Approved indications
- Skeletal muscle relaxation during surgery
Common side effects
- Hypotension
- Bradycardia
- Respiratory depression
Key clinical trials
- Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes (NA)
- Muscle Relaxation for Pediatric Adenotonsillectomy (PHASE4)
- Venous Cannulation Pain to Guide Choice of Anesthetic Method (NA)
- COnventional Vs. Optimised PERiprocedural Analgosedation Vs. Total IntraVEnous Anaesthesia for Pulsed-Field Ablation (COOPERATIVE-PFA) (PHASE3)
- The Effect of Deep Neuromuscular Block and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Shoulder Surgery Using a Deltopectoral Approach (PHASE4)
- Open and Laparoscopic Total Extraperitoneal Repair Under Spinal Anesthesia Versus General Anesthesia (NA)
- Ketamine Versus Dexmedetomidine for Prevention of Postoperative Delirium (NA)
- Opioid Free Anesthesia and Major Spine Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Repeated rocuronium dose CI brief — competitive landscape report
- Repeated rocuronium dose updates RSS · CI watch RSS
- University Hospital, Antwerp portfolio CI